Literature DB >> 26349765

The Epigenetic Reader BRD2 as a Specific Modulator of PAI-1 Expression in Lipopolysaccharide-Stimulated Mouse Primary Astrocytes.

Chang Soon Choi1, Seong Hwi Hong2, Seobo Sim3,4, Kyu Suk Cho1, Ji-Woon Kim1, Sung Min Yang1, Se Jin Jeon5, Jueng Soo You6,7,8, Chan Young Shin9,10,11.   

Abstract

The post translational modification of lysine acetylation is a key mechanism that regulates chromatin structure. Epigenetic readers, such as the BET domains, are responsible for reading histone lysine acetylation which is a hallmark of open chromatin structure, further providing a scaffold that can be accessed by RNA polymerases as well as transcription factors. Recently, several reports have assessed and highlighted the roles of epigenetic readers in various cellular contexts. However, little is known about their role in the regulation of inflammatory genes, which is critical in exquisitely tuning inflammatory responses to a variety of immune stimuli. In this study, we investigated the role of epigenetic readers BRD2 and BRD4 in the lipopolysaccharide (LPS)-induced immune responses in mouse primary astrocytes. Inflammatory stimulation by LPS showed that the levels of Brd2 mRNA and protein were increased, while Brd4 mRNA levels did not change. Knocking down of Brd2 mRNA using specific small interfering RNA (siRNA) in cultured mouse primary astrocytes inhibited LPS-induced mRNA expression and secretion of plasminogen activator inhibitor-1 (PAI-1). However, no other pro-inflammatory cytokines, such as Il-6, Il-1β and Tnf-α, were affected. Indeed, treatment with bromodomain-containing protein inhibitor, JQ1, blocked Pai-1 mRNA expression through the inhibition of direct BRD2 protein-binding and active histone modification on Pai-1 promoter. Taken together, our data suggest that BRD2 is involved in the modulation of neuroinflammatory responses through PAI-1 and via the regulation of epigenetic reader BET protein, further providing a potential novel therapeutic strategy in neuroinflammatory diseases.

Entities:  

Keywords:  Astrocyte; BRD2; Inflammation; JQ1; Plasminogen activator inhibitor-1

Mesh:

Substances:

Year:  2015        PMID: 26349765     DOI: 10.1007/s11064-015-1710-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  32 in total

Review 1.  Phenotypic plasticity and the epigenetics of human disease.

Authors:  Andrew P Feinberg
Journal:  Nature       Date:  2007-05-24       Impact factor: 49.962

Review 2.  Tissue plasminogen activator: beyond thrombolysis.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

3.  DNA sequence and structure of the mouse RING3 gene: identification of variant RING3 transcripts.

Authors:  K L Thorpe; S Beck
Journal:  Immunogenetics       Date:  1998-06       Impact factor: 2.846

Review 4.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

5.  The bromodomain-containing gene BRD2 is regulated at transcription, splicing, and translation levels.

Authors:  Enyuan Shang; Qingping Cui; Xiangyuan Wang; Cheryl Beseler; David A Greenberg; Debra J Wolgemuth
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

6.  Immunostimulation of rat primary astrocytes decreases intracellular ATP level.

Authors:  C Y Shin; J W Choi; J R Ryu; J H Ryu; W Kim; H Kim; K H Ko
Journal:  Brain Res       Date:  2001-06-01       Impact factor: 3.252

7.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

8.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

9.  A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator.

Authors:  G V Denis; M R Green
Journal:  Genes Dev       Date:  1996-02-01       Impact factor: 11.361

10.  Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins.

Authors:  Sebastian Wienerroither; Isabella Rauch; Felix Rosebrock; Amanda M Jamieson; James Bradner; Matthias Muhar; Johannes Zuber; Mathias Müller; Thomas Decker
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

View more
  6 in total

1.  Integrated Analysis of Mouse and Human Gastric Neoplasms Identifies Conserved microRNA Networks in Gastric Carcinogenesis.

Authors:  Zheng Chen; Zheng Li; Mohammed Soutto; Weizhi Wang; M Blanca Piazuelo; Shoumin Zhu; Yan Guo; Maria J Maturana; Alejandro H Corvalan; Xi Chen; Zekuan Xu; Wael M El-Rifai
Journal:  Gastroenterology       Date:  2018-11-28       Impact factor: 22.682

Review 2.  BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Authors:  Dequina A Nicholas; Guillaume Andrieu; Katherine J Strissel; Barbara S Nikolajczyk; Gerald V Denis
Journal:  Cell Mol Life Sci       Date:  2016-08-04       Impact factor: 9.261

Review 3.  BET bromodomains as novel epigenetic targets for brain health and disease.

Authors:  Mandakini B Singh; Gregory C Sartor
Journal:  Neuropharmacology       Date:  2020-09-15       Impact factor: 5.250

Review 4.  Chemical probes targeting epigenetic proteins: Applications beyond oncology.

Authors:  Suzanne Ackloo; Peter J Brown; Susanne Müller
Journal:  Epigenetics       Date:  2017-01-12       Impact factor: 4.528

Review 5.  The BET family in immunity and disease.

Authors:  Nian Wang; Runliu Wu; Daolin Tang; Rui Kang
Journal:  Signal Transduct Target Ther       Date:  2021-01-19

Review 6.  Pharmacological Modulation of BET Family in Sepsis.

Authors:  Nian Wang; Runliu Wu; Paul B Comish; Rui Kang; Daolin Tang
Journal:  Front Pharmacol       Date:  2021-03-11       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.